Incretin / GLP-1 Compounds

Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with established cardiovascular benefit.

Dual GIP/GLP-1 receptor agonist producing greater average weight loss than semaglutide in head-to-head trials.

Investigational triple agonist (GLP-1, GIP, glucagon) producing the largest weight loss seen in Phase II trials to date.

Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).

Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.

Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.

Fixed combination of cagrilintide (amylin analog) and semaglutide, studied for additive weight loss in obesity and T2D.

Oral triple monoamine reuptake inhibitor investigated for obesity; shows substantial weight loss in trials.

Dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim; holds FDA Breakthrough Therapy designation for MASH with fibrosis.

Pfizer oral GLP-1R agonist. Program discontinued April 2025 after a case of drug-induced liver injury despite meeting PK targets.

Pfizer once-daily oral GLP-1R agonist. Discontinued June 2023 due to elevated transaminases across the program.

Fully human mAb against activin type-II receptors. Failed sarcopenia and sIBM endpoints; now developed by Lilly for obesity in combination with tirzepatide (BELIEVE trial).

Proapoptotic peptidomimetic targeting prohibitin on adipose vasculature. Induced obesity regression in primates but nephrotoxicity limits translation.

First-generation once-daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Still widely prescribed and referenced as the baseline comparator for newer GLP-1 agents.

Once-weekly GLP-1 receptor agonist approved for type 2 diabetes (2014) with demonstrated cardiovascular benefit in the REWIND trial. One of the three major established GLP-1 drugs alongside semaglutide and liraglutide.

The first GLP-1 receptor agonist ever approved (2005), originally derived from Gila monster venom (exendin-4). Available in twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations.